Tirzepatide is typically prescribed for adults with a BMI of 30 or higher, or those with a BMI of 27 or higher who have weight-related health conditions such as diabetes, sleep apnea, or high cholesterol
Baar MP, Brandt RMC, Putavet DA, et al
The injections are typically administered in the arm, thigh, abdomen, or buttocks areas with more subcutaneous fatty tissue
The extensive clinical trial programme for semaglutide, including the STEP (Semaglutide Treatment Effect in People with obesity) trials, did not identify nightmares as a significant adverse event associated with the medication
The structural models of GHSR with the antagonist C12 and the neurotensin-NTSR-Gi complex used in this study are available in the Protein Data Bank database under accession codes 6KO5 and 6OS9